The development of this new formulation took several years and was spearheaded by OU chemistry professor Charles Rice, PhD.
Regarding the process of treating deadly infections like MRSA, Dr. Rice told the Transcript, “The doctor will keep giving you [antibiotic] options until eventually you have to go to the drug of last resort…throughout that process, the patient suffers…what our discovery does is provide an option to the medical community earlier in the process, so we can stop MRSA before it causes patient harm and raises hospital costs.”
According to the CDC, an estimated 72,444 people became infected with MRSA in 2014, resulting in 9,194 deaths.
Find more information on antibiotic resistance here.
More articles on infection control:
NIH, CDC to collaborate on infectious disease training program for at-risk workers
Another potential Elizabethkingia case under investigation in Wisconsin
National collaboration shows promise for CAUTI reduction
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
